The telomerase peptide vaccine UV1 induces Th1 immune response targeting tumor cells and is used with pembrolizumab (anti-PD-1) in a phase-I clinical trial (NCT03538314), with nivolumab (anti-PD-1) and ipilimumab in two randomized phase II clinical trials in malignant melanoma (NCT04382664) and mesothelioma (ClinicalTrials.gov Identifier: NCT04300244), with Durvalumab (anti-PD-L1) and Olaparib (PARP inhibitor) in relapsed ovarian cancer (ClinicalTrials.gov Identifier: NCT04742075) and with Pembrolizumab in head and neck cancer (ClinicalTrials.gov Identifier: NCT05075122). This evidence concerns the gene PDCD1 and melanoma.